Could Prostate Drugs Reduce Parkinson’s Disease Risk

Prostate issues are prevalent in adult men and can be a disturbing problem for most of them. Although there are treatments and medications to help, the researchers are adamant about finding the best possible cure to the problem.

Interestingly, these medications do not only support the prostate, but there have been some new and surprising discoveries lately.

According to a new study, Terazosin, a prostate drug that repurposes Glycolysis, was effective in reducing the chances of Parkinson’s disease in men.

Medical News Today shares the stories of research based on Glycolysis enhancement to reduce Parkinson’s disease.

A Word on Parkinson’s Disease

Typically, Parkinson’s Disease is considered a neurological problem due to the lack of dopamine inside the brain. Moreover, its symptoms can worsen with time and lead to further complications, like difficulty eating, speaking, chewing, etc.

Non-Motor Impacts

On the other hand, there are non-motor impacts of the disease too. It can cause dementia, sleep loss, depression, and lack of energy. These effects may be secondary as Parkinson’s disease mainly targets motor operations.

Common Signs of Parkinson’s Disease

Some of the common signs of Parkinson’s disease are as follows:

  • Difficulty in walking
  • Cramped handwriting
  • Tremors
  • Inability to smell
  • Poor body balance
  • Sleep problems
  • Facial masking
  • Change in vocals
  • Bradykinesia
  • Constipation
  • Weight loss
  • Hunched postures
  • Psychological problems


There are numerous treatments for the symptoms, but there is no cure to the problem just yet. Generally, most treatments focus on upheaving the dopamine levels. 

Interestingly, the recent research results indicate that we can enhance the energy levels through a metabolic pathway, Glycolysis.

How Glycolysis Works with Parkinson’s Disease

Since Glycolysis is an energy source, it can generically help most cell operations in the body. In terms of priority, Glycolysis is the first metabolic pathway that produces energy.  

A study in 2014 suggested how early signs of Parkinson’s disease directly impact the glucose metabolism in the body. Another similar study in 2019 found that increased energy production can delay many of Parkinson’s disease symptoms.

Terazosin and Parkinson’s Disease

Parkinson’s disease symptoms reduce with Terazosin. A study concluded that the prostate drug enhances the energy inside the cells. It does so by improving the enzyme activity that breaks down glucose from Glycolysis.

As a result, researchers are now focusing on how Glycolysis can help with Parkinson’s disease. Primarily, the testing focuses on animals and clinical databases to understand the effects. 

The earlier findings indicate that Parkinson’s disease patients who used the drug had delayed symptoms of the disease.

Research on Terazosin

To understand the impacts of Terazosin, an international team of researchers at the University of Iowa has started new studies of Glycolysis enhancing drugs. The idea is to observe the effectiveness and possible treatment options for Parkinson’s disease.

US and Denmark Research

One such research took the stage in Denmark from 1996 to 2017. The researchers gathered data from three health registries. Additionally, there was more information collected from the Truven Health Analytics Marketscan database from 2001 to 2017.

Patients having Parkinson’s disease who took the medication within one year of the diagnosis were excluded from the research. Moreover, there were no female participants.

The researchers began collecting data during the first year of medication, and it continued till they removed the patients from the list.

Drugs that Reduce the Risk of Parkinson’s

Terazosin was up against another drug called Tamsulosin. The researchers compared the results of the two drugs to understand which one showed more efficacy.

After data collection, the researchers matched the results for Tamsulosin and Terazosin users. In the Danish Cohort, there were nearly 52,300 pairs with an average age of 67.9 years. 

On the other hand, while the Truven cohort contained more than 94,800 pairs at an average age of 63.8 years.


The results suggested that patients with glycolysis drugs had lesser chances of Parkinson’s development than those who took Tamsulosin. In terms of the cohort, the Glycolysis consuming Danish cohort was at a 12% lower risk, while the Truven cohort had a 37% lower chance.

Furthermore, glycolysis drugs also reduced Parkinson’s risk if the patients continued to take the medication. 

Even though researchers simulated both the research in precisely similar environments, they believe minor design differences brought about different results.

The authors suggest that although the designs and definitions were almost parallel, the healthcare systems and the two countries’ coding practices were somewhat a hindrance to the useful comparison of the results.

Additional Elements to the Drug and the Study

There can be more risk factors attached to the development of Parkinson’s. However, the study did not focus on them, which could mean that the results need reconsideration to a certain extent. 

For instance, conditions like head trauma, exposure to pesticides can increase Parkinson’s risk, but they weren’t considered.

However, the researchers are convinced that the glucose enhancing drug can help glucose impairment in patients affected by Parkinson’s.

Moreover, the study focuses on men, so Terazosin may not be an ideal solution to reduce Parkinson’s in women. Ultimately, there must be a different treatment for them.


A review in 2019 from the Journal of Parkinson’s Disease mentioned how the risk could be twice as much in men than women. However, it develops quicker in women than in men, which contributes to the higher mortality rate.

The study on Parkinson’s disease was observational research, so there is a need for further investigation to conclude any fruitful outcomes. 

Moreover, there is room for more comprehensive research environments that can ensure more accurate and traceable results in the future.

Was this article helpful?
Close Bitnami banner